In spite of extensive research no reliable method exists for the control of digitalis therapy. As there are great individual variations * in tolerance to the drug it is often difficult to know if a patient really receives an 'optimal' dose of digitalis. Especially in some patients with rapid arrhythmias or uncharacteristic tiredness, it may be difficult to know whether more or less digitalis should be given. The high frequency of digitalis intoxications reported (Chung, I969; Dubnow and Burchell, I965; Hurwitz and Wade, I969; J0rgensen v and S0rensen, I970; Shapiro et al., I969) further emphasizes the need for controlling digitalis therapy by new objective methods. One method may be the estimation of the glycoside concentration in plasma. In recent years, different principles for determination of digoxin in plasma have been developed (Brooker and Jelliffe, I969;  Jelliffe, I966; Lowenstein, I965; Smith, Butler, and Haber, I969) ; for a review, see Smith and Haber (I970) . In I966, Lowenstein and Corrill described a method based on the ability of cardiac glycosides to inhibit the uptake of 86Rb in erythrocytes. After modification by Bertler and Redfors (197ob) this method got a good sensitivity and precision comparable to the radioimmunoassay recently published by Smith et al. (I969) .
The limited results obtained so far with the above-mentioned methods, indicate that oral therapeutic doses of digoxin give plasma concentrations of only a few ng/ml (Bertler and Redfors, I970b; Binnion et al., I969; Chamberlain et al., 1970; Evered, Chapman, and Hayter, I970; Grahame-Smith and Everest, I969; Lowenstein and Corrill, I966; Smith et al., I969) . Despite the low plasma levels and the narrow therapeutic range of the glycoside, such methods may act as a guide to distinguish patients with from patients without digitalis intoxication (Chamberlain et al., I970; i969; Redfors and Bertler, I970; Smith et al., I969) .
In the present study on patients with atrial fibrillation the relation between dosage and plasma concentration of digoxin has been 
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Note: Clinical grades are classified according to the New York Heart Association as modified by Bishop and Wade (1963) . In patients not previously digitalized clinical grades after digitalization are shown in parentheses.
examined. The plasma levels were related to the clinical effects of different digoxin doseschanges in subjective symptoms, physical working capacity, and ventricular rate at rest and during exercise.
Subjects and methods
In a dose-response study ii patients with atrial fibrillation were investigated. The diagnoses and some other clinical data are given in Table i . A more detailed presentation of the patient material has previously been published (Redfors, I97Ia).
All patients were given successively increasing digoxin doses, OI25, 0.25, 0o375, 0o50, 0o75, and i-oo mg/day until symptoms or signs of digitalis intoxication appeared. The drug was given once a day in the morning. The dosage was unknown to the patients, and was changed every i4th day. Tablets containing varying amounts of digoxin for the different treatment periods were specially prepared for the investigation.' At the beginning of the study two patients were still undigitalized; the others had been given a stable maintenance dose of digoxin, mostly 0o375 mg/day, for at least 14 days.
At the end of each I4 days' period of treatment, the patients were subjected to a careful physical examination including a thorough history. Electrocardiograms were recorded at rest and during an exercise tolerance test. Blood samples were drawn for analysis of plasma digoxin concentration, erythrocyte sedimentation rate, haemoglobin, and potassium in serum. The examinations were always carried out at the same time in the morning, starting about Is hours after a light, standardized meal. The methods used to evaluate the different clinical effects of the digoxin treatment -changes in subjective symptoms, physical working capacity, and ventricular rate at rest and during exercise -have been described previously (Redfors, 197Ia) .
The following analyses were also performed in Table 2 .
Estimation of plasma digoxin concentration At the beginning of the investigation the original digoxin assay described by Lowenstein and Corrill (I966) was used. However, not until a systematic study of the method had been performed and certain modifications introduced, did the method gain the accuracy, precision, and sensitivity necessary to an investigation of this kind. The digoxin assay has been described in detail elsewhere (Bertler and Redfors, I970b) . To study its reliability, each of I5 separate pools of plasma containing 0o5 to I9 ng digoxin/ml was analysed in repeated triplicate determinations on 5 different days; between the triplicate determinations a standard deviation of o-i ng/ml was found. The lower limit of sensitivity was 0o3 ng/ml (3 SD) (Bertler and Redfors, I970b) . In order to study the 'absorption curves' of digoxin, blood samples were at every examination drawn also at go and i8o minutes after the administration of the daily maintenance dose of the period. Later on, plasma digoxin values were measured in all i i patients before and 3O, 6o, go, I20, and i8o minutes after administration of 0o375 mg digoxin. The patients had received this dose once daily for at least I4 days.
Results
The plasma concentrations of digoxin registered before administration of the daily maintenance dose on the last day of each period of treatment are presented in Fig. i . As can be seen, the plasma digoxin concentration increases linearly with increasing digoxin dose. The differences in plasma levels registered at adjacent digoxin doses were significant. At doses of 0o25 and 0o50 mg dixogin/day, the mean plasma concentration was 0o7 and iz2 ng/ml, respectively. The plasma concentration increased more slowly in patients who tolerated high dixogin doses; thus, the plasma level at toxicity, mean i-6 ng/ml, became less scattered (range I 3-I-9). The correlation between plasma concentration and digoxin dosage was highly significant (r = o 9I). The patients received increasing digoxin doses until minor symptoms of digitalis toxicity appeared. Most patients developed gastrointestinal symptoms, which rapidly disappeared when the dose again was reduced. At the end of the study an ' optimal' dose was decided for each patient (Redfors, I97Ia) .
This dose was chosen to afford a reasonable margin of safety to the toxic limit (Table 3) . The margin was somewhat modified by the individual degree of improvement observed during the study; thus, the dyspnoea and tiredness at exertion experienced by the patients during the different treatment periods were taken into consideration. The mean 'optimal' dose was for the II patients 0'43 mg/day, constituting nearly 70 per cent of the toxic dose, which on the average was o 63 mg/day. At the 'optimal' dose a mean plasma digoxin concentration of i i ng/ml was found (Table 3) . (Fig. 2) , that is to the toxic limit, in all patients estimated in the same, standardized way. A similar high correlation (r = -o83) was found simply by plotting the plasma values against the toxic doses. The mean plasma levels at 0o375 mg digoxin/day were also significantly correlated to the 'optimal' dosage ( Fig. 3) . High plasma values thus indicated that the patients had reached or were near the toxic limit, and low plasma values indicated that the dose could be further increased. That occasional patients may show a divergent reaction to the glycoside was in this study exemplified by one man (Case I2) weighing 96 kg, who developed toxic symptoms at a plasma level of only 0o7 ng/ml, when he had received o0375 mg digoxin/day for a few days (Table 3) . His electrolytes were normal as well as his renal, liver, and thyroid function tests (Table 2) . At the toxic dosage he also showed a divergent response to exercise with very rapid ventricular rate at low work loads in spite of a good physical working capacity (Redfors, 197Ib) . It may be mentioned that he had always been very prone to develop motion sickness.
Plasma digoxin values, registered go and I80 minutes after administration of the different digoxin maintenance doses, were about 3 and 2 times as high, respectively, as the plasma levels before the intake of the daily dose. Means and standard deviations of ithe values registered at the different digoxin doses are given in Table 4 . The mean plasma concentration was 4-2 ng/ml go minutes after administration of the digoxin doses which gave toxic symptoms.
The variability of plasma digoxin concentration in the first hours after oral administration of 0o375 mg digoxin is further presented in Table 5 . Great differences were found between patients regarding both plasma levels and the profiles of the curves (Fig. 4) . These characteristic profiles of the individual plasma digoxin curves were at repeated examinations essentially the same.
In the present study the subjective tiredness and dyspnoea decreased when the digoxin dosage was increased from the insufficient dose of 0o125 mg/day (Redfors, I97Ia ). There were great individual differences in the response to the treatment, but the mean improvement was well related to the dosage up to an 'optimal' dose level, where the doseresponse curve levelled off. A similar relation was found between the physical working capacity estimated at exercise tests and the digoxin dosage (Redfors, I97Ib) . The plasma digoxin concentration increased fairly linearly with increasing doses up to the toxic limit (Fig. i) . The correlation between dosage and plasma levels was much better than it was between the dosage and the subjective symptoms or physical working capacity. These two facts may ' explain' that there was not always a good correlation in individual cases between changes of plasma digoxin levels and the changes of subjective improvement on each dose step.
Ventricular rate at rest and during exercise, measured at strictly standardized conditions, decreased significantly at increasing digoxin dosage (Redfors, I97ib) . A corresponding slowing of ventricular rate was found at increasing plasma digoxin concentrations (Fig.  5) 
2-8
Mean +SD 1I0 +0-2 2-3 ±I0 3-± +0-7 2-8 ±0-5 2-6 o-6 2-2 o-6 "11-
on the ability of digoxin to inhibit the 86Rb uptake in erythrocytes, originally described by Lowenstein and #= 'optimal' doses of the other patients.
and plasma sampling and to relate obtained values to 'normal values' for the specific interval used (Bertler and Redfors, I970a) . The increase in plasma digoxin levels in the first hours after oral administration of the glycoside was in the present study of the same magnitude as that found by Marcus et al. (I966) and greater than that recently reported by Evered et al. (1970) . The individual variations in the shape of the plasma concentration curves (Fig. 4) indicate that a fairly long interval is preferable. In order to get a relative 'steady state' condition, which would probably most reliably reflect the pharmacologically active digoxin concentration in the myocardium, an interval of 24 hours was chosen between the last dose and blood sampling. This routine also gave a good reproducibility between days. Plasma digoxin concentrations at a certain dosage (o0375 mg/day) were significantly negatively correlated both to the 'optimal' dosage and the toxic limit of the patients, ex-0.5 1.0 1.5 2.0 group.bmj.com on October 30, 2017 -Published by http://heart.bmj.com/ Downloaded from pressed as the total amount of digoxin administered from the O-I25 mg period until symptoms of toxicity developed. Thus, there may be a possibility to predict an adequate digoxin dosage for a patient from determinations of 'steady state' plasma digoxin concentrations at lower digoxin doses. Such an application of the method would be of great clinical value, and may help to prevent digitalis intoxication, which seems to increase in frequency (Dubnow and Burchell, I965; Hurwitz and Wade, I969; J0rgensen and S0rensen, I970) . That a similar prediction from ventricular rate at rest or exercise is very inaccurate has previously been shown in this study (Redfors, I97Ib The individual tolerance to digitalis was in this study at least partly shown to be due to factors that determine the concentration of digoxin in plasma -absorption, tissue distribution, metabolism, or excretion. It has I previously not been possible to analyse the significance of the absorption of the glycoside, without administration of isotopically labelled digitalis preparations. Though the variations of the plasma digoxin concentration registered during the first hours after dose administration may depend on other factors, it seems *-most natural to assume that these individual variations are due to relatively pronounced differences in the ability of drug absorption (Bertler and Redfors, 197oa; Wilson, I969) . To study this problem more complete kinetic studies, with estimation of the digoxin content in faeces, urine, and tissues are now in prowgress using the present 86Rb method.
Reduced renal function is known to modify plasma digoxin levels and tolerance to digitalis (Doherty, I968; Jelliffe, I968) . In the present study the renal function of all patients was mainly within normal limits, which may explain that the correlations between the creatinine and digoxin clearances and the toxic dosages were only probably significant. An average of about 6o per cent of the daily maintenance dose of o0375 mg was found in the urine. The relevance in the present patient material of some other factors, which can affect the individual tolerance to digitalis, is discussed separately (Redfors, 197Ia (Redfors, 197Ib) . The relations between the plasma and myocardial digoxin concentrations and the digitalis induced arrhythmias are insufficiently known (Marcus, I969; Smith and Haber, 1970 
